Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990223022> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W1990223022 endingPage "263" @default.
- W1990223022 startingPage "262" @default.
- W1990223022 abstract "The high rate of relapse after cessation of nucleos(t)ide analogues (NUCs) treatment in chronic hepatitis B (CHB) patients leads us to reassess the feasibility for off-therapy, but long-term follow-up data are scarce. We assessed the feasibility for off-therapy by a long-term observation of relapse in response to lamivudine (LAM) and telbivudine (LdT). Eighty-six NUC-naive CHB patients, treated with LAM (n = 46) or LdT (n = 40) who reached the guidelines recommended for off-therapy, were followed for up to 10 years. Hepatitis B virus (HBV), viral serology and biochemistries were periodically determined. COX model was used to predict the risk of relapse. A total of 52.3% of patients experienced relapse within a median of 115 months (range, 61–122 months). A total of 93.3% of relapses occurred within 48 months. Relapse rates in hepatitis B e antigen (HBeAg)-positive (n = 56) and HBeAg-negative (n = 30) patients were 39.3% and 76.7%, respectively (p < 0.01). HBeAg-positive patients who achieved an early viral response (EVR), defined as undetectable HBV DNA within 6 months, had a lower relapse rate compared to non-EVR patients (21.4% vs. 59.2%, p < 0.01). EVR patients who had both lower HBV DNA (<106 copies/mL) at baseline and lower hepatitis B surface antigen (HBsAg) at end of treatment had a relapse rate of 10.7%. The high relapse rates in CHB patients over this 10-year follow-up make LAM or LdT off therapy infeasible in most of the cases, except in the case of HBsAg loss and/or seroconversion. HBeAg-positive patients with EVR, lower HBV DNA and HBsAg had lower relapse rates and could be good candidates for off-therapy. Long-term monitoring, especially during the first 4 years, is critical for patients off-therapy." @default.
- W1990223022 created "2016-06-24" @default.
- W1990223022 creator A5010167619 @default.
- W1990223022 creator A5020997688 @default.
- W1990223022 creator A5026689356 @default.
- W1990223022 creator A5038143970 @default.
- W1990223022 creator A5085575155 @default.
- W1990223022 date "2003-01-01" @default.
- W1990223022 modified "2023-10-15" @default.
- W1990223022 title "220 Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial" @default.
- W1990223022 doi "https://doi.org/10.1016/s0270-9139(03)80263-x" @default.
- W1990223022 hasPublicationYear "2003" @default.
- W1990223022 type Work @default.
- W1990223022 sameAs 1990223022 @default.
- W1990223022 citedByCount "20" @default.
- W1990223022 countsByYear W19902230222012 @default.
- W1990223022 crossrefType "journal-article" @default.
- W1990223022 hasAuthorship W1990223022A5010167619 @default.
- W1990223022 hasAuthorship W1990223022A5020997688 @default.
- W1990223022 hasAuthorship W1990223022A5026689356 @default.
- W1990223022 hasAuthorship W1990223022A5038143970 @default.
- W1990223022 hasAuthorship W1990223022A5085575155 @default.
- W1990223022 hasConcept C126322002 @default.
- W1990223022 hasConcept C203014093 @default.
- W1990223022 hasConcept C2522874641 @default.
- W1990223022 hasConcept C2775940106 @default.
- W1990223022 hasConcept C2777382497 @default.
- W1990223022 hasConcept C2777410769 @default.
- W1990223022 hasConcept C2777869810 @default.
- W1990223022 hasConcept C2780593183 @default.
- W1990223022 hasConcept C2781144229 @default.
- W1990223022 hasConcept C71924100 @default.
- W1990223022 hasConcept C90924648 @default.
- W1990223022 hasConceptScore W1990223022C126322002 @default.
- W1990223022 hasConceptScore W1990223022C203014093 @default.
- W1990223022 hasConceptScore W1990223022C2522874641 @default.
- W1990223022 hasConceptScore W1990223022C2775940106 @default.
- W1990223022 hasConceptScore W1990223022C2777382497 @default.
- W1990223022 hasConceptScore W1990223022C2777410769 @default.
- W1990223022 hasConceptScore W1990223022C2777869810 @default.
- W1990223022 hasConceptScore W1990223022C2780593183 @default.
- W1990223022 hasConceptScore W1990223022C2781144229 @default.
- W1990223022 hasConceptScore W1990223022C71924100 @default.
- W1990223022 hasConceptScore W1990223022C90924648 @default.
- W1990223022 hasLocation W19902230221 @default.
- W1990223022 hasOpenAccess W1990223022 @default.
- W1990223022 hasPrimaryLocation W19902230221 @default.
- W1990223022 hasRelatedWork W1587600912 @default.
- W1990223022 hasRelatedWork W2035092770 @default.
- W1990223022 hasRelatedWork W2048131794 @default.
- W1990223022 hasRelatedWork W2069771342 @default.
- W1990223022 hasRelatedWork W2370038091 @default.
- W1990223022 hasRelatedWork W2387708376 @default.
- W1990223022 hasRelatedWork W2393464793 @default.
- W1990223022 hasRelatedWork W3030031493 @default.
- W1990223022 hasRelatedWork W3031271030 @default.
- W1990223022 hasRelatedWork W4250145802 @default.
- W1990223022 hasVolume "38" @default.
- W1990223022 isParatext "false" @default.
- W1990223022 isRetracted "false" @default.
- W1990223022 magId "1990223022" @default.
- W1990223022 workType "article" @default.